Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.71 |
| ▸ | GSK3A | P49840 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537422 | 0.94 | GSK3B (0.64) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL8231814 | 0.86 | GSK3B (0.67) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722032 | 0.86 | GSK3B (0.67) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722618 | 0.86 | GSK3B (0.67) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722165 | 0.86 | GSK3B (0.67) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13722726 | 0.86 | GSK3B (0.86) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13711325 | 0.85 | GSK3B (0.69) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL13910520 | 0.85 | GSK3B (0.72) | GSK3BCYP2D6CYP1A2 | |
| SCHEMBL8232940 | 0.85 | GSK3B (0.78) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A | |
| SCHEMBL537379 | 0.85 | GSK3B (0.64) | GSK3BCYP2D6CYP1A2CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-7572793-B2 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7572793-B2 | 3-Substituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-11 | — | — | US | disclosed |
| WO-2007011065-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | HRH4, HNMT, CYP3A4 | GSK3B 972/4885CYP2D6 25/4885CYP1A2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.